Omalizumab updosing allows disease activity control in patients with refractory chronic spontaneous urticaria.
Curto-Barredo L, Spertino J, Figueras-Nart I, Expósito-Serrano V, Guilabert A, Melé-Ninot G, Cubiró X, Bonfill-Ortí M, Garcias-Ladaria J, Villar M, García-Navarro X, Bielsa-Marsol I, Vilavella M, Aparicio G, Baliu-Piqué C, Álvarez A, Lamas-Domenech N, Duran-Jordà X, Serra-Baldrich E, Giménez-Arnau A.
Curto-Barredo L, et al. Among authors: cubiro x.
Br J Dermatol. 2018 Jul;179(1):210-212. doi: 10.1111/bjd.16379. Epub 2018 Apr 25.
Br J Dermatol. 2018.
PMID: 29368377
No abstract available.